First Bank & Trust Buys Shares of 8,031 BridgeBio Pharma, Inc. (NASDAQ:BBIO)

First Bank & Trust bought a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,031 shares of the company’s stock, valued at approximately $248,000.

Several other institutional investors have also recently made changes to their positions in the stock. Diversified Trust Co raised its stake in shares of BridgeBio Pharma by 2.5% in the third quarter. Diversified Trust Co now owns 17,111 shares of the company’s stock worth $451,000 after buying an additional 411 shares during the period. Parkman Healthcare Partners LLC raised its stake in shares of BridgeBio Pharma by 0.7% in the fourth quarter. Parkman Healthcare Partners LLC now owns 100,734 shares of the company’s stock worth $4,067,000 after buying an additional 734 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of BridgeBio Pharma by 1.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 65,773 shares of the company’s stock worth $2,655,000 after buying an additional 904 shares during the period. Assetmark Inc. raised its stake in shares of BridgeBio Pharma by 46.8% in the fourth quarter. Assetmark Inc. now owns 2,931 shares of the company’s stock worth $118,000 after buying an additional 935 shares during the period. Finally, Quarry LP bought a new position in shares of BridgeBio Pharma in the fourth quarter worth about $50,000. Institutional investors own 99.85% of the company’s stock.

Insider Buying and Selling at BridgeBio Pharma

In other news, Director Randal W. Scott sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $28.84, for a total value of $28,840.00. Following the completion of the sale, the director now directly owns 5,500 shares of the company’s stock, valued at approximately $158,620. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 24.66% of the stock is currently owned by company insiders.

BridgeBio Pharma Stock Performance

NASDAQ BBIO opened at $25.33 on Friday. The business has a 50 day simple moving average of $27.38 and a two-hundred day simple moving average of $31.58. BridgeBio Pharma, Inc. has a 1-year low of $16.61 and a 1-year high of $44.32.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.35. The firm had revenue of $211.12 million for the quarter, compared to analysts’ expectations of $140.06 million. As a group, equities analysts anticipate that BridgeBio Pharma, Inc. will post -3.2 EPS for the current year.

Analyst Upgrades and Downgrades

BBIO has been the topic of several recent research reports. Mizuho decreased their price objective on BridgeBio Pharma from $60.00 to $53.00 and set a “buy” rating on the stock in a research note on Tuesday, March 5th. Bank of America cut their target price on BridgeBio Pharma from $50.00 to $42.00 and set a “buy” rating for the company in a research report on Tuesday, June 25th. Cantor Fitzgerald reiterated an “overweight” rating and set a $70.00 target price on shares of BridgeBio Pharma in a research report on Tuesday, May 28th. UBS Group cut their target price on BridgeBio Pharma from $51.00 to $47.00 and set a “buy” rating for the company in a research report on Tuesday, May 28th. Finally, Raymond James initiated coverage on BridgeBio Pharma in a research report on Thursday, March 21st. They set an “outperform” rating and a $45.00 target price for the company. Two investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $47.21.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.